David Young

CIK: 0001378166

Transaction Breakdown

Open Market Buys (P)8 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)2 (12.5%)

Derivative conversions

Awards (A)5 (31.3%)

Compensation grants

Other (G, F, J, C, D, …)1 (6.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PCSA

Processa Pharmaceuticals, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (16 total)

PCSA
Processa Pharmaceuticals, Inc.
Jun 30, 2026
Purchase(P)
Direct
2.5K shares at avg. $1.93$5K
PCSA
Processa Pharmaceuticals, Inc.
Jun 15, 2026
Purchase(P)
Direct
2.1K shares at avg. $2.22$5K
PCSA
Processa Pharmaceuticals, Inc.
May 29, 2026
Purchase(P)
Direct
1.8K shares at avg. $2.57$5K
PCSA
Processa Pharmaceuticals, Inc.
May 15, 2026
Purchase(P)
Direct
1.5K shares at avg. $2.97$5K
PCSA
Processa Pharmaceuticals, Inc.
Apr 30, 2026
Purchase(P)
Direct
1.7K shares at avg. $2.69$5K
PCSA
Processa Pharmaceuticals, Inc.
Apr 15, 2026
Purchase(P)
Direct
1.5K shares at avg. $2.97$5K
PCSA
Processa Pharmaceuticals, Inc.
Mar 31, 2026
Purchase(P)
Direct
1.8K shares at avg. $2.54$5K
PCSA
Processa Pharmaceuticals, Inc.
Jan 1, 2026
Exercise(M)
Direct
49 shares-
PCSA
Processa Pharmaceuticals, Inc.
Oct 1, 2025
Award(A)
Restricted Stock Units
Direct
111K shares-
PCSA
Processa Pharmaceuticals, Inc.
Oct 1, 2025
Award(A)
Stock Options (Right to Buy)
Direct
333K shares-
PCSA
Processa Pharmaceuticals, Inc.
Jul 24, 2025
Award(A)
Restricted Stock Units
Direct
1.8M shares-
PCSA
Processa Pharmaceuticals, Inc.
Apr 1, 2025
Tax Payment(F)
Direct
5.3K shares at avg. $0.41$2K
PCSA
Processa Pharmaceuticals, Inc.
Apr 1, 2025
Exercise(M)
Direct
17.3K shares-
PCSA
Processa Pharmaceuticals, Inc.
Jan 29, 2025
Award(A)
Warrants
Direct
124.5K shares-
PCSA
Processa Pharmaceuticals, Inc.
Jan 29, 2025
Award(A)
Warrants
Direct
62.3K shares-
PCSA
Processa Pharmaceuticals, Inc.
Jan 27, 2025
Purchase(P)
Direct
124.5K shares at avg. $0.80$99K

		Type	Shares	Price		Ownership
Jun 30, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	2,531	$1.93	$4,885	Direct
Jun 15, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	2,067	$2.22	$4,589	Direct
May 29, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,786	$2.57	$4,590	Direct
May 15, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,545	$2.97	$4,589	Direct
Apr 30, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,706	$2.69	$4,589	Direct
Apr 15, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,545	$2.97	$4,589	Direct
Mar 31, 2026	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	1,810	$2.54	$4,588	Direct
Jan 1, 2026	PCSA Processa Pharmaceuticals, Inc.	Exercise(M)	49	-	$0	Direct
Oct 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	111,000	-	-	Direct
Oct 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Stock Options (Right to Buy)	333,000	-	-	Direct
Jul 24, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Restricted Stock Units	1,813,133	-	-	Direct
Apr 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Tax Payment(F)	5,345	$0.41	$2,202	Direct
Apr 1, 2025	PCSA Processa Pharmaceuticals, Inc.	Exercise(M)	17,272	-	-	Direct
Jan 29, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Warrants	124,500	-	-	Direct
Jan 29, 2025	PCSA Processa Pharmaceuticals, Inc.	Award(A) Warrants	62,250	-	-	Direct
Jan 27, 2025	PCSA Processa Pharmaceuticals, Inc.	Purchase(P)	124,500	$0.80	$99,289	Direct

1-16 of 16 transactions

About Young David

Young David (SEC CIK 0001378166) files insider reports with the SEC as Pres. Research & Development of Processa Pharmaceuticals, Inc. (PCSA).

Signal8 holds 14 ownership filings by Young David, all Form 4s, filed between Jan 29, 2025 and Jul 1, 2026. Those filings report 16 transactions, from Jan 27, 2025 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Young David's filings is in VERO BEACH, FL.

Recent filings by Young David

Jun 30, 2026: Open-market purchase of PCSA shares (Form 4, code P).
Jun 15, 2026: Open-market purchase of PCSA shares (Form 4, code P).
May 29, 2026: Open-market purchase of PCSA shares (Form 4, code P).
May 15, 2026: Open-market purchase of PCSA shares (Form 4, code P).
Apr 30, 2026: Open-market purchase of PCSA shares (Form 4, code P).

Other insiders filing for Processa Pharmaceuticals, Inc. (PCSA)

Ng George K, Chief Executive Officer
GUJRATHI SHEILA, Director
Yorke Justin W, Director
SKIBSTED RUSSELL, Chief Financial Officer
Pannu Geraldine, Director
Neal James R, Director

How to read Form 4 transaction codes